(RYTM) Rhythm Pharmaceuticals - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 5.972m | Total Return 50.8% in 12m

Stock: Rare Diseases, Obesity, Treatments, Medications

Total Rating 33
Risk 41
Buy Signal -0.68
Biotechnology +5.4
Biotechnology +5.9
Market Cap: 5,972m
Avg Trading Vol: 76.6M USD
ATR: 6.70%
Peers RS (IBD): 37.8
Risk 5d forecast
Volatility 51.6%
Relative Tail Risk -6.14%
Reward TTM
Sharpe Ratio 0.90
Alpha 44.32
Character TTM
Beta 0.681
Beta Downside 0.524
Drawdowns 3y
Max DD 32.48%
CAGR/Max DD 2.08

EPS (Earnings per Share)

EPS (Earnings per Share) of RYTM over the last years for every Quarter: "2021-03": -1.16, "2021-06": -0.7, "2021-09": -0.7, "2021-12": -0.85, "2022-03": -1.05, "2022-06": -0.89, "2022-09": -0.79, "2022-12": -0.75, "2023-03": -0.92, "2023-06": -0.82, "2023-09": -0.76, "2023-12": -0.7, "2024-03": -2.35, "2024-06": -0.69, "2024-09": -0.73, "2024-12": -0.72, "2025-03": -0.81, "2025-06": -0.75, "2025-09": -0.82, "2025-12": -0.73,
EPS CAGR: 5.73%
EPS Trend: 15.0%
Last SUE: 0.18
Qual. Beats: 0

Revenue

Revenue of RYTM over the last years for every Quarter: 2021-03: 0.035, 2021-06: 0.274, 2021-09: 1.028, 2021-12: 1.817, 2022-03: 1.498, 2022-06: 9.066, 2022-09: 4.284, 2022-12: 8.79, 2023-03: 11.469, 2023-06: 19.221, 2023-09: 22.504, 2023-12: 24.234, 2024-03: 25.967, 2024-06: 29.078, 2024-09: 33.251, 2024-12: 41.83, 2025-03: 32.704, 2025-06: 48.502, 2025-09: 51.298, 2025-12: 57.253,
Rev. CAGR: 164.21%
Rev. Trend: 75.0%
Last SUE: 0.21
Qual. Beats: 0

Description: RYTM Rhythm Pharmaceuticals March 06, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) is a commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases. The companys primary focus is on IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist.

IMCIVREE is approved for specific genetic obesity disorders, including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and leptin receptor (LEPR) deficiency obesities, as well as Bardet-Biedl and Alström syndromes. These conditions represent ultra-orphan diseases, a segment of the biotechnology sector characterized by high unmet medical need and often premium pricing for approved therapies.

RYTM is also conducting Phase 3 clinical trials for IMCIVREE in other MC4R pathway disorders, such as POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 (SRC1) deficiency obesity, and SH2B1 deficiency obesity. The company has established several licensing and collaboration agreements, common in the biotechnology industry for expanding market reach and sharing development costs.

To deepen your understanding of RYTMs market position and financial health, further research on ValueRay could be beneficial.

Headlines to watch out for

  • IMCIVREE sales growth drives revenue expansion
  • Clinical trial success expands IMCIVREEs addressable market
  • Regulatory approvals critical for new indications
  • Competition from new obesity treatments impacts market share
  • Licensing agreements provide additional revenue streams

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income: -196.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.24 > 0.02 and ΔFCF/TA 14.99 > 1.0
NWC/Revenue: 190.2% < 20% (prev 198.8%; Δ -8.56% < -1%)
CFO/TA -0.24 > 3% & CFO -115.7m > Net Income -196.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.41 > 1.5 & < 3
Outstanding Shares: last quarter (66.9m) vs 12m ago 8.57% < -2%
Gross Margin: 89.73% > 18% (prev 0.90%; Δ 8.88k% > 0.5%)
Asset Turnover: 43.45% > 50% (prev 33.17%; Δ 10.28% > 0%)
Interest Coverage Ratio: -8.52 > 6 (EBITDA TTM -174.1m / Interest Expense TTM 20.6m)

Altman Z'' -11.09

A: 0.75 (Total Current Assets 466.9m - Total Current Liabilities 105.9m) / Total Assets 481.2m
B: -2.81 (Retained Earnings -1.35b / Total Assets 481.2m)
C: -0.40 (EBIT TTM -175.5m / Avg Total Assets 436.7m)
D: -3.95 (Book Value of Equity -1.35b / Total Liabilities 342.1m)
Altman-Z'' Score: -11.09 = D

Beneish M -3.14

DSRI: 0.97 (Receivables 26.1m/18.5m, Revenue 189.8m/130.1m)
GMI: 1.00 (GM 89.73% / 89.73%)
AQI: 0.59 (AQ_t 0.02 / AQ_t-1 0.04)
SGI: 1.46 (Revenue 189.8m / 130.1m)
TATA: -0.17 (NI -196.5m - CFO -115.7m) / TA 481.2m)
Beneish M-Score: -3.14 (Cap -4..+1) = AA

What is the price of RYTM shares?

As of March 27, 2026, the stock is trading at USD 81.90 with a total of 913,652 shares traded.
Over the past week, the price has changed by -9.31%, over one month by -16.49%, over three months by -25.55% and over the past year by +50.83%.

Is RYTM a buy, sell or hold?

Rhythm Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RYTM.
  • StrongBuy: 8
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the RYTM price?

Issuer Target Up/Down from current
Wallstreet Target Price 137.6 68%
Analysts Target Price 137.6 68%

RYTM Fundamental Data Overview March 24, 2026

P/S = 31.4693
P/B = 42.9393
Revenue TTM = 189.8m USD
EBIT TTM = -175.5m USD
EBITDA TTM = -174.1m USD
Long Term Debt = 3.99m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.95m USD (from shortTermDebt, last quarter)
Debt = 246.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 192.2m USD (from netDebt column, last quarter)
Enterprise Value = 5.83b USD (5.97b + Debt 246.5m - CCE 388.9m)
Interest Coverage Ratio = -8.52 (Ebit TTM -175.5m / Interest Expense TTM 20.6m)
EV/FCF = -49.98x (Enterprise Value 5.83b / FCF TTM -116.6m)
FCF Yield = -2.00% (FCF TTM -116.6m / Enterprise Value 5.83b)
FCF Margin = -61.46% (FCF TTM -116.6m / Revenue TTM 189.8m)
Net Margin = -103.6% (Net Income TTM -196.5m / Revenue TTM 189.8m)
Gross Margin = 89.73% ((Revenue TTM 189.8m - Cost of Revenue TTM 19.5m) / Revenue TTM)
Gross Margin QoQ = 91.61% (prev 89.28%)
Tobins Q-Ratio = 12.11 (Enterprise Value 5.83b / Total Assets 481.2m)
Interest Expense / Debt = 1.87% (Interest Expense 4.62m / Debt 246.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -138.6m (EBIT -175.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.41 (Total Current Assets 466.9m / Total Current Liabilities 105.9m)
Debt / Equity = 1.77 (Debt 246.5m / totalStockholderEquity, last quarter 139.1m)
Debt / EBITDA = -1.10 (negative EBITDA) (Net Debt 192.2m / EBITDA -174.1m)
Debt / FCF = -1.65 (negative FCF - burning cash) (Net Debt 192.2m / FCF TTM -116.6m)
Total Stockholder Equity = 109.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.00% (Net Income -196.5m / Total Assets 481.2m)
RoE = -179.1% (Net Income TTM -196.5m / Total Stockholder Equity 109.8m)
RoCE = -154.2% (out of range, set to none) (EBIT -175.5m / Capital Employed (Equity 109.8m + L.T.Debt 3.99m))
RoIC = -188.0% (out of range, set to none) (NOPAT -138.6m / Invested Capital 73.7m)
WACC = 8.08% (E(5.97b)/V(6.22b) * Re(8.35%) + D(246.5m)/V(6.22b) * Rd(1.87%) * (1-Tc(0.21)))
Discount Rate = 8.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.28%
[DCF] Fair Price = unknown (Cash Flow -116.6m)
EPS Correlation: 15.03 | EPS CAGR: 5.73% | SUE: 0.18 | # QB: 0
Revenue Correlation: 75.01 | Revenue CAGR: 164.2% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.79 | Chg7d=-0.019 | Chg30d=-0.093 | Revisions Net=-6 | Analysts=11
EPS current Year (2026-12-31): EPS=-3.07 | Chg7d=-0.086 | Chg30d=-0.432 | Revisions Net=-10 | Growth EPS=+1.2% | Growth Revenue=+51.7%
EPS next Year (2027-12-31): EPS=-0.33 | Chg7d=-0.254 | Chg30d=-0.564 | Revisions Net=-5 | Growth EPS=+89.2% | Growth Revenue=+89.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Next Quarter)

Additional Sources for RYTM Stock

Fund Manager Positions: Dataroma | Stockcircle